Drug

NAD

In clinical development

Emerging researchLate-stage developmentSteady momentum

Also known as Beta-Nicotinamide Adenine Dinucleotide, Codehydrase I, Codehydrogenase I, Coenzyme I+17 more

Beta-Nicotinamide Adenine Dinucleotide, Codehydrase I, Codehydrogenase I, Coenzyme I, Cozymase I, DPN, Diphosphopyridine nucleotide, NADIDE, NICOTINAMIDE ADENINE DINUCLEOTIDE, Nadida, Nadidum, Nicotinamide dinucleotide, Nicotinamide-adenine dinucleotide, Nicotineamide adenine dinucleotide, Oxidized diphosphopyridine nucleotide, beta-Diphosphopyridine nucleotide, beta-NAD, beta-NAD+, nicotinamide adenine dinucleotide (NAD), NAD+, Pyridine, nucleotide diphosphate.

RxNorm1044975 ChEMBLCHEMBL1234613UNII0U46U6E8UK

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Pilot Randomized Controlled Study of Combinatorial Gerotherapeutics for Healthspan Improvement

Clinical trial2026-04-01Primary completion · ClinicalTrials.gov

Pathobiochemistry of Aging and Neurodegeneration: Deregulation of NAD+ Metabolism in Brain Cells.

Research2024-12-06Biomolecules

The therapeutic perspective of NAD+ precursors in age-related diseases.

Research2024-02-02Biochemical and biophysical research communications

NAD+, Axonal Maintenance, and Neurological Disease.

Research2023-09-07Antioxidants & redox signaling

NAD+ Precursors and Intestinal Inflammation: Therapeutic Insights Involving Gut Microbiota.

Research2023-06-30Nutrients

The autophagy-NAD axis in longevity and disease.

Research2023-03-05Trends in cell biology

Pilot Study Into Low Dose Naltrexone (LDN) and Nicotinamide Adenine Dinucleotide (NAD+) for Treatment of Patients With Post-COVID-19 Syndrome (Long-COVID19)

Clinical trial2023-01-23Completed · ClinicalTrials.gov

Regulation of SIRT1 and Its Roles in Inflammation.

Research2022-03-11Frontiers in immunology

NAD+ improves cognitive function and reduces neuroinflammation by ameliorating mitochondrial damage and decreasing ROS production in chronic cerebral hypoperfusion models through Sirt1/PGC-1α pathway.

Research2021-09-16Journal of neuroinflammation

NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STING.

Research2021-09-01Proceedings of the National Academy of Sciences of the United States of America

NAD+ homeostasis in human health and disease.

Research2021-05-27EMBO molecular medicine

NAD+ metabolism, stemness, the immune response, and cancer.

Research2021-01-01Signal transduction and targeted therapy

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

NAD

Aliases & brands

Beta-Nicotinamide Adenine DinucleotideCodehydrase ICodehydrogenase ICoenzyme ICozymase IDPNDiphosphopyridine nucleotideNADIDENICOTINAMIDE ADENINE DINUCLEOTIDENadidaNadidumNicotinamide dinucleotideNicotinamide-adenine dinucleotideNicotineamide adenine dinucleotideOxidized diphosphopyridine nucleotidebeta-Diphosphopyridine nucleotidebeta-NADbeta-NAD+nicotinamide adenine dinucleotide (NAD)NAD+Pyridine, nucleotide diphosphate

RxNorm CUI

1044975

ChEMBL ID

CHEMBL1234613

UNII

0U46U6E8UK

Clinical trials

2 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2023

Active studies

Late-stage (III+)

Completed

PHASE DISTRIBUTIONn = 2

Phase 21Phase 31

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Pilot Randomized Controlled Study of Combinatorial Gerotherapeutics for Healthspan Improvement

Active, not recruitingPH IIIAgelessRxn=302026

Recent completions

Trials that read out recently, adding to the completed evidence base.

Pilot Study Into Low Dose Naltrexone (LDN) and Nicotinamide Adenine Dinucleotide (NAD+) for Treatment of Patients With Post-COVID-19 Syndrome (Long-COVID19)

CompletedPH IIAgelessRxn=362023

Research activity

15 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20172024

Most influential

NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Signal transduction and targeted therapy · 2020 · 754 cites

Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity.

Nature · 2017 · 550 cites

Regulation of SIRT1 and Its Roles in Inflammation.

Frontiers in immunology · 2022 · 387 cites

NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STING.

Proceedings of the National Academy of Sciences of the United States of America · 2021 · 387 cites

NAD+ metabolism, stemness, the immune response, and cancer.

Signal transduction and targeted therapy · 2021 · 379 cites

De novo NAD+ synthesis enhances mitochondrial function and improves health.

Nature · 2018 · 348 cites

Related diseases

6 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Neurodegenerative Diseases3 Alzheimer's Disease2 Disease Models, Animal2 Inflammation2 Neoplasms2 Neuroinflammatory Diseases2

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Choline

Studied across 2 of the same disease areas as NAD in the shared literature.

2 shared diseases1 shared paper

Nicotinamide Mononucleotide

Frequently co-studied with NAD in the research literature.

1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials